NASDAQ$NUWE

Nuwellis Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Nuwellis reported a record quarter revenue with strong pediatric sales and expanding margins.

Nuwellis, Inc. reported a 9% increase in revenue for the fourth quarter of 2023, reaching $2.6 million, driven by growth in pediatric revenue and increased disposable utilization. The company is focused on expanding the use of Aquadex into new clinical applications and has taken steps to reduce its monthly cash burn rate.

  • Revenue for the fourth quarter of 2023 was $2.6 million, a 9% increase compared to the prior-year period.
  • Fourth quarter pediatric revenue grew 35% year over year, with a 28% increase in utilization and a 49% increase in console sales.
  • Gross margin was 54.4% for the fourth quarter of 2023.
  • The company reduced its monthly cash burn rate by approximately 40%.

Headline financials

Total Revenue

$2.55M

Previous: $2.34M+9.1%
EPS (adj)

-$78.40

Previous: -$175.00+55.2%
Gross Margin

54.4%

Previous: 56.9%-4.4%
Capital Expenditures

$36K

Previous: $19K+89.5%
Net Income

-$5.51M

Previous: -$1.9M-189.9%
Operating Income

-$3.59M

Previous: -$4.53M+20.8%
Gross Profit

$1.39M

Previous: $1.33M+4.3%
R&D Expense

$1.37M

No prior period
Stock-Based Comp

$157K

Previous: $165K-4.8%

Revenue & EPS history

Nuwellis · Revenue · Quarterly

$2.55M

Q4 2023+9.1%vs Q4 2022
Beat estimate in 4 of 14 quarters(29%)
ActualEstimate

Forward guidance

Nuwellis anticipates a strong revenue year in 2024, driven by clinical superiority of Aquadex over diuretics, new products for existing pediatric customers, completion of the DaVita Pilot phase, and the IDE submission for its pediatric dedicated renal disease device branded Vivian. The company is balancing these growth catalysts with the need to raise capital and has taken steps to reduce its monthly cash burn rate by approximately 40%.

Tailwinds

  • Clinical superiority of Aquadex over diuretics.
  • New products for existing pediatric customers.
  • Completion of the DaVita Pilot phase.
  • IDE submission for pediatric dedicated renal disease device Vivian.
  • Reduced monthly cash burn rate by approximately 40%.

Headwinds

  • Need to raise capital this year.
  • Tougher capital market conditions for microcap companies.
  • Hospital budgetary constraints.
  • Nursing shortages.
  • Balancing growth initiatives with cost reduction.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-5.5%

Avg return

Earnings day

-10.5%

Avg return

5 days after

-18.5%

Avg return

30 days after

28%

15 / 54 earnings

Positive

+51.9%

Q1 2024

Best reaction

-29.9%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-5.0%-86.3%
Q4 2025+2.4%-2.3%-16.3%
Q3 2025-3.4%-11.9%-18.0%
Q2 2025+0.4%+8.4%-24.0%
Q1 2025-3.1%-5.1%-68.7%
Q4 2024-4.0%-7.9%-25.4%
Q3 2024+6.6%-0.6%-28.2%
Q2 2024-14.3%-30.2%-46.4%
Q1 2024+51.9%+47.1%+29.4%
Q4 2023-20.7%-18.3%-36.7%
Q3 2023-10.0%-12.9%-14.3%
Q2 2023-5.1%-3.0%-22.2%
Q1 2023-29.9%-37.8%-34.6%
Q4 2022-5.1%-6.5%-41.2%
Q3 2022-19.6%-16.7%-50.0%
Q2 2022-6.5%-4.2%+23.9%
Q1 2022+1.0%+2.9%-7.4%
Q4 2021-1.2%-6.1%+2.0%
Q3 2021-17.0%-13.2%-33.3%
Q2 2021+9.6%+7.9%+3.0%
Q1 2021-14.6%-8.9%+6.6%
Q4 2020+5.7%-6.2%-21.3%
Q3 2020-7.8%-7.0%+14.1%
Q2 2020-16.0%-32.0%-68.0%
Q1 2020-9.6%-14.6%+2.4%
Q4 2019-28.8%-33.9%-29.0%
Q3 2019-15.0%-23.0%-16.0%
Q2 2019-1.2%+2.0%+0.4%
Q1 2019-13.3%-13.3%-24.9%
Q4 2018-12.6%-25.6%-69.8%
Q3 2018+2.8%+4.7%-21.7%
Q2 2018-26.4%-37.4%-23.9%
Q1 2018-17.1%-18.8%-23.3%
Q4 2017-15.5%-25.7%-21.0%
Q3 2017-12.8%-15.6%-47.3%
Q2 2017-4.0%-13.3%-6.7%
Q1 2017-9.5%-1.4%-9.5%
Q4 2016-5.3%-12.0%-58.0%
Q3 2016-5.0%-5.0%+190.0%
Q2 2016-14.9%-16.0%-17.0%
Q1 2016+1.5%
Q4 2015-15.9%
Q3 2015-1.2%
Q2 2015+0.7%
Q1 2015-3.5%
Q4 2014-0.2%
Q3 2014-17.5%
Q2 2014+23.9%
Q1 2014+3.2%
Q4 2013+2.1%
Q1 2013+6.2%
Q4 2012+2.6%
Q2 2012-7.6%
Q4 2011+0.0%
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro